Updates to the Handbook

Updates throughout the chapter to reflect the addition of the hexavalent Vaxelis vaccine on the National Immunisation Program.

Updates throughout the chapter to reflect the introduction of the hexavalent Vaxelis vaccines on the National Immunisation Program.

Additional detail also provided in the Epidemiology section of the chapter.

Updates throughout the chapter to reflect introduction of hexavalent Vaxelis vaccine on the National Immunisation Program.

Additionally, updates made to the Epidemiology section of the chapter.

Updates to recommendations and information on National Immunisation Program funded vaccines to reflect GRADE assessment of meningococcal vaccines.

Updated List. Specified medical conditions associated with increased risk of invasive meningococcal disease.

Updates to Variations from product information section for Bexsero.

Updates throughout the chapter to reflect the introduction of the hexavalent Vaxelis vaccine to the National Immunisation Program.

Additionally, updates made to the Epidemiology section of the chapter.

Updates throughout the chapter to reflect the introduction of hexavalent Vaxelis vaccine on the National Immunisation Program.

Updates made to the Epidemiology section.

Updates to Table. Components of vaccines used in Australia to reflect introduction of Vaxelis vaccine and amend ingredients for existing vaccines.

Updates throughout the chapter to reflect the introduction of the hexavalent Vaxelis vaccine on the National Immunisation Program.

Additionally, updates also made to the Epidemiology section.

Updates to clinical guidance for Hib vaccine to reflect the introduction of hexavalent Vaxelis vaccine. 

Updates to clinical guidance throughout the chapter to improve clarity and provide further guidance regarding injection sites, positioning for vaccination, vaccine injection techniques, distraction techniques, use of vaccines in multidose vials, giving multiple vaccine injections at the same visit.

Updates throughout the chapter to improve clarity of information and provide up-to-date guidance.

Updates to Epidemiology section to provide the most up-to-date information.

Updates to guidance in NHIG as prophylaxis in Public Health Management section to reflect most up-to-date information.

Updates to clinical guidance to align with current recommendations and funding for meningococcal catch up vaccination.

Updates to clinical guidance have been made throughout the chapter in line with the 2023 ATAGI annual statement for seasonal influenza vaccines.

Updated information is provided on influenza vaccination and influenza activity in the context of COVID-19 vaccination and the COVID-19 pandemic.

Updates to clinical guidance throughout the chapter to include interim recommendations for extended valency vaccines (Vaxneuvance [15vPCV] and Prevenar 20 [20vPCV]) in adults for whom they have recently been registered by the TGA but are not currently funded under the National Immunisation Program.

Updates to the Table. Components of vaccines used in Australia to include cell-based influenza vaccine (Flucelvax Quad) and 20-valent pneumococcal conjugate vaccine (Prevenar 20).

Updates to clinical guidance in multiple sections to reflect the addition of a 20-valent pneumococcal conjugate vaccine.

Updates to reflect addition of 20vPCV in Table. Vaccines that are not routinely recommended in pregnancy: inactivated bacterial vaccines.

Updates to guidance regarding HPV vaccination for catch-up of people ≥10 years of age (for vaccines recommended on a population level).